The short answer
A body of work has examined melanocortin peptides in models of neural injury. Catania reviewed neuroprotective actions of melanocortins in Trends in Neurosciences in 2008, and Giuliani and colleagues examined MC4R-stimulating melanocortins in cerebral ischaemia models in Endocrinology in 2006.
Key facts
- Catania 2008
- Trends Neurosci review (PMID 18550183)
- Giuliani 2006
- Endocrinology (PMID 16254026)
- Receptor implicated
- MC4R
- Model
- Cerebral ischaemia, in animals
- Notable design feature
- Early and delayed treatment compared
- Human evidence
- Not established
Why melanocortins were examined in the brain at all
Melanocortin receptors are not confined to skin and adrenal tissue. MC3R and MC4R are expressed centrally, which is why the same receptor family that governs pigmentation also participates in energy balance. Central expression makes neural effects a coherent hypothesis rather than a stretch.
What the 2006 work examined
Giuliani and colleagues compared both early and delayed treatment with MC4R-stimulating melanocortins in cerebral ischaemia. Testing delayed as well as early administration is the more demanding design. An intervention that only works if given before or immediately at injury has limited relevance, since real injuries are not anticipated.
Research material referenced
Semax 10mg, third-party HPLC tested
Why the delayed arm is the informative one
Many interventions protect tissue in animal ischaemia models when given prophylactically. Very few retain effect when administration is delayed, and that gap is a major reason neuroprotection findings have translated poorly from animals to humans. A study reporting both is testing the harder and more relevant question.
What the review contributed
Catania described neuroprotective actions of melanocortins as a therapeutic opportunity in Trends in Neurosciences in 2008. A review in a journal of that kind indicates the field considered the finding worth surveying, and the word opportunity conveys the stage accurately, then and arguably now.
Why this connects to Semax without transferring to it
Semax derives from the same precursor region, so this literature is context for the family. But Semax replaces positions 8 to 10 with Pro-Gly-Pro, and those replaced residues are part of the melanocortin receptor-binding core that MT-2 is built around. A compound that discards the receptor core is not straightforwardly described by findings about receptor-stimulating melanocortins.
What is not being claimed
Anything about neuroprotection in any person. This is animal model literature and a review of it, reported as what was measured and in what model. Semax holds no marketing authorisation from the MHRA, EMA or FDA and is supplied here for laboratory research only.
Frequently asked questions
Are melanocortin receptors present in the brain?
Yes. MC3R and MC4R are expressed centrally, which is why the same family that governs pigmentation also participates in energy balance.
Why does delayed treatment matter?
Many interventions protect in animal ischaemia models when given prophylactically; few retain effect when delayed, and real injuries are not anticipated.
Does this literature apply to Semax?
Only as family context. Semax replaces positions 8 to 10, which are part of the receptor-binding core these studies concern.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedCatania A, Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends Neurosci 2008 (PMID 18550183)pubmed.ncbi.nlm.nih.gov
- PubMedGiuliani D et al., Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology 2006 (PMID 16254026)pubmed.ncbi.nlm.nih.gov
- PubMedDores RM: Ann N Y Acad Sci 2011 (PMID 21388402)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Semax (ACTH Fragment Peptide) articles
- A Mechanism Layer Below Gene ExpressionKolbaev 2025 examined Semax and calcium dynamics in rat brain neurons - a faster timescale than the neurotrophin expression work.
- What the Animal Behavioural Work ReportsGlazova 2021 examined Semax against alterations following early-life fluvoxamine exposure in rats. Why the model design is the interesting part.
- What a Fragment Keeps Decides What It DoesThree fragments of alpha-MSH pursue pigmentation, inflammation and cognition. The difference is not the parent - it is which residues each retained.
- What Is Semax? Origin, Sequence and Neurotrophin MechanismSemax is a synthetic heptapeptide derived from an ACTH fragment, developed in Russia. Structure, neurotrophin mechanism and regulatory status.
- Is Semax Really an ACTH(4-10) Analogue?Semax is universally called an ACTH(4-10) analogue, but shares only residues 4-7. Pro-Gly-Pro replaces Arg-Trp-Gly, and that substitution is the point.